Alpha 2.0
Login Register
» Articles » PMID: 30590239

Adherence to Oral Disease-modifying Therapy in Multiple Sclerosis Patients: A Systematic Review

Overview
Journal Mult Scler Relat Disord
Specialty Neurology
Date 2018 Dec 28
PMID 30590239
Citations 7
Authors
Ee Ling Yoon
Wing Loong Cheong
Affiliations
Soon will be listed here.
Citing Articles

Real-world persistence of multiple sclerosis disease-modifying therapies.

Tallantyre E, Dobson R, Froud J, St John F, Anderson V, Arun T Eur J Neurol. 2024; 31(7):e16289.

PMID: 38567516 PMC: 11235620. DOI: 10.1111/ene.16289.

Disease modifying therapies for multiple sclerosis: benefit and acceptability.

Harrison J, Hill J, Palmer K Br J Neurosci Nurs. 2024; 18(Sup3):S16-S19.

PMID: 38213413 PMC: 7615514. DOI: 10.12968/bjnn.2022.18.Sup3.S16.

Relationship between Patient Preferences, Attitudes to Treatment, Adherence, and Quality of Life in New Users of Teriflunomide.

Strosova D, Tuzil J, Turkova B, Pilnackova B, de Souza L, Dolezalova H Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297360 PMC: 9609230. DOI: 10.3390/ph15101248.

Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review.

Washington F, Langdon D J Neurol. 2021; 269(4):1861-1872.

PMID: 34676448 PMC: 8940867. DOI: 10.1007/s00415-021-10850-w.

Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.

Mardan J, Hussain M, Allan M, Grech L J Manag Care Spec Pharm. 2021; 27(9):1273-1295.

PMID: 34464209 PMC: 10391062. DOI: 10.18553/jmcp.2021.27.9.1273.